Medicine – Haemochromatosis

Haemochromatosis is a disorder of excessive body iron accumulation caused by increased intestinal iron absorption. Over time, excess iron is deposited in organs such as the liver, pancreas, heart, joints, skin and endocrine glands, where it can produce progressive tissue injury.

The classic inherited form is:

Hereditary haemochromatosis.

1. Inheritance

The common HFE-associated form of hereditary haemochromatosis is inherited in an:

Autosomal recessive – AR pattern.

This means clinically important disease generally develops when a person inherits pathogenic variants affecting both copies of the relevant gene.

2. HFE Gene

The common form is associated with abnormalities in the:

HFE gene

located on:

Chromosome 6.

The most important variant is:

C282Y.

Another common variant is:

H63D.

3. Important Genetic Clarification

The original notes list:

C282Y and H63D mutations.

This is broadly correct, but the strongest association with classical clinically significant HFE haemochromatosis is:

C282Y homozygosity.

H63D alone usually has much lower penetrance and is much less likely to cause severe iron overload.

Some individuals are:

C282Y/H63D compound heterozygotes,

but clinically significant iron overload is still much less predictable than in C282Y homozygotes.

4. Basic Pathophysiology

The central abnormality is inappropriate increase in:

Intestinal iron absorption.

Normally iron absorption is tightly controlled because the body has no effective physiological mechanism for excreting large amounts of excess iron.

5. Role of Hepcidin

A key regulator is:

Hepcidin.

Hepcidin is produced mainly by the:

Liver.

It reduces iron entry into the circulation by causing internalisation and degradation of:

Ferroportin.

6. Ferroportin

Ferroportin is an iron export protein found on cells such as:

Enterocytes.

Macrophages.

When hepcidin activity is inadequate:

Ferroportin remains active.

Therefore more iron enters the bloodstream.

7. Mechanism in HFE Haemochromatosis

The simplified pathway is:

HFE abnormality

↓

Inappropriately low hepcidin activity

↓

Increased ferroportin activity

↓

Increased intestinal iron absorption

↓

Progressive iron accumulation

↓

Organ damage.

8. Why Men Are More Commonly and Severely Affected

The original notes correctly state that haemochromatosis is:

More commonly clinically apparent and often more severe in men.

Premenopausal women lose iron through:

Menstruation

and

Pregnancy.

This delays iron accumulation.

Therefore women may present later, often after:

Menopause.

9. Clinical Penetrance

An important modern point is that not every person with a susceptible HFE genotype develops severe clinical disease.

This is called:

Incomplete penetrance.

Disease severity depends on factors such as:

Sex.

Age.

Alcohol intake.

Other liver disease.

Metabolic risk factors.

10. Liver Disease

The liver is one of the major organs affected by iron deposition.

Progressive iron accumulation can cause:

Hepatomegaly.

Fibrosis.

Cirrhosis.

Therefore the original association with:

Liver cirrhosis

is correct.

11. Hepatocellular Carcinoma

Patients who develop haemochromatosis-related cirrhosis have an increased risk of:

Hepatocellular carcinoma – HCC.

This risk is particularly associated with established:

Cirrhosis or advanced fibrosis.

Therefore preventing advanced hepatic iron injury is an important objective of early diagnosis and treatment.

12. Skin Bronzing

The original notes correctly include:

Skin bronzing.

Skin pigmentation results from a combination of:

Increased melanin

and

Iron deposition.

The skin may develop a:

Bronze or slate-grey appearance.

13. Diabetes Mellitus

Iron can accumulate in the:

Pancreas.

Damage to pancreatic beta cells and associated metabolic disturbances can lead to:

Diabetes mellitus.

The traditional combination of:

Bronze skin + diabetes

gave rise to the historical term:

“Bronze diabetes.”

14. Arthropathy

Joint disease is an important manifestation of haemochromatosis.

Patients may develop:

Chronic arthropathy.

Classically affected joints include the:

Second and third metacarpophalangeal joints.

15. Chondrocalcinosis

The original notes correctly include:

Chondrocalcinosis.

Haemochromatosis is associated with deposition of:

Calcium pyrophosphate crystals.

This can produce:

CPPD disease

and may resemble:

Pseudogout.

Therefore:

HAEMOCHROMATOSIS + MCP ARTHROPATHY + CHONDROCALCINOSIS

is a useful examination association.

16. Cardiomyopathy

Iron deposition in cardiac tissue can cause:

Cardiomyopathy.

The heart may develop:

Systolic dysfunction.

Diastolic dysfunction.

Arrhythmias.

Advanced disease can result in:

Heart failure.

17. Endocrine Manifestations

Iron can also accumulate in endocrine organs.

Possible consequences include:

Hypogonadism.

Loss of libido.

Erectile dysfunction.

Infertility.

Other endocrine abnormalities may occur in severe iron overload.

18. Typical Clinical Features – Note Form

Liver:

Hepatomegaly.

Fibrosis.

Cirrhosis.

Increased HCC risk when cirrhosis is present.

Skin:

Bronze or slate-grey pigmentation.

Pancreas:

Diabetes mellitus.

Joints:

MCP arthropathy.

Chondrocalcinosis.

CPPD/pseudogout.

Heart:

Cardiomyopathy.

Arrhythmias.

Heart failure.

Endocrine system:

Hypogonadism.

Reduced libido.

Sexual dysfunction.

19. Diagnosis

The original notes include:

Raised serum iron and ferritin.

Increased transferrin saturation.

HFE genetic testing.

Liver biopsy.

These remain relevant, but the modern diagnostic approach places particular emphasis on:

Transferrin saturation and ferritin, followed by appropriate genetic testing.

20. Transferrin Saturation

Transferrin saturation – TSAT measures the proportion of transferrin binding sites occupied by iron.

It is calculated from measures of circulating iron and transferrin or total iron-binding capacity.

In hereditary haemochromatosis, TSAT is often:

Elevated early.

A persistent TSAT around:

≥45%

commonly raises suspicion for iron overload, although thresholds and interpretation depend on the clinical context and laboratory.

21. Serum Ferritin

Ferritin reflects:

Stored iron.

Ferritin may rise progressively as iron stores increase.

However, ferritin is also an:

Acute-phase reactant.

Therefore it can be elevated by:

Inflammation.

Infection.

Alcohol-related liver disease.

Metabolic liver disease.

Other liver injury.

So:

HIGH FERRITIN ≠ AUTOMATICALLY HAEMOCHROMATOSIS.

22. Serum Iron

Serum iron may be elevated, but it fluctuates and is not usually interpreted alone.

More informative measurements include:

Transferrin saturation

and

Ferritin.

23. Genetic Testing

If biochemical iron studies suggest hereditary haemochromatosis, genetic testing may identify:

HFE variants.

Particular attention is given to:

C282Y.

Testing can help distinguish inherited HFE haemochromatosis from secondary iron overload.

24. C282Y Homozygosity

The classic genotype is:

C282Y/C282Y.

However, genotype alone does not necessarily mean severe clinical disease.

The degree of actual iron loading should still be assessed with:

Ferritin.

Transferrin saturation.

Evidence of organ involvement.

25. Role of Liver MRI

A major modern addition is:

MRI assessment of liver iron.

MRI can estimate hepatic iron concentration non-invasively and may help determine:

The extent of iron overload

and

Whether tissue deposition is significant.

26. Liver Biopsy

The original notes include:

Liver biopsy.

Historically, biopsy was commonly used to confirm hepatic iron deposition and assess fibrosis.

Today, biopsy is:

Not routinely required for every patient.

It is more likely to be considered when:

The diagnosis is uncertain.

Advanced fibrosis/cirrhosis needs clarification.

Another liver disease is suspected.

27. Histology

When biopsy is performed, iron can be demonstrated using:

Perls’ Prussian blue stain.

In hereditary haemochromatosis, iron classically accumulates initially in:

Hepatocytes.

With increasing severity, deposition becomes more widespread.

28. Treatment

The central treatment for hereditary haemochromatosis is:

Therapeutic venesection – phlebotomy.

This is the treatment of choice for most suitable patients with significant iron overload.

29. Mechanism of Venesection

Removal of blood removes:

Red blood cells containing haemoglobin-bound iron.

The body then uses stored iron to produce replacement red cells.

Repeated venesection therefore gradually reduces:

Total body iron stores.

30. Initial Venesection Phase

During the iron-depletion phase, blood is removed repeatedly according to:

Haemoglobin.

Ferritin.

Clinical tolerance.

The aim is to bring iron stores into an appropriate low-normal target range without causing:

Anaemia.

31. Maintenance Treatment

After excess iron has been removed, patients may require:

Maintenance venesection

at intervals to prevent reaccumulation.

The frequency varies substantially between individuals.

32. Desferrioxamine

The original notes include:

Desferrioxamine, also spelled:

Deferoxamine.

This is an:

Iron-chelating drug.

It binds iron and facilitates its elimination.

33. Is Deferoxamine Routine Treatment for Hereditary Haemochromatosis?

This requires an important correction.

For typical hereditary haemochromatosis, the preferred treatment is:

VENesection / phlebotomy.

Iron chelation is generally reserved for patients in whom venesection is:

Contraindicated, poorly tolerated, or impossible.

For example, venesection may be difficult in patients with significant:

Anaemia.

34. Other Iron Chelators

Other chelating agents include:

Deferasirox.

Deferiprone.

These are used more commonly in certain forms of:

Secondary/transfusional iron overload

than in routine HFE haemochromatosis.

35. Venesection Versus Chelation – Note Form

Hereditary haemochromatosis:

Excess iron but generally adequate red-cell production.

↓

Blood can be removed.

↓

VENesection is preferred.

Transfusional iron overload with chronic anaemia:

Removing blood may worsen anaemia.

↓

IRON CHELATION is often preferred.

This distinction is very important.

36. Effects of Treatment

Venesection can improve or prevent progression of several manifestations, particularly if started before irreversible organ damage develops.

It may improve:

Fatigue.

Liver abnormalities.

Skin pigmentation.

Some metabolic abnormalities.

37. Less Reversible Manifestations

Some complications may not completely reverse even after iron removal.

These include established:

Cirrhosis.

Arthropathy.

Advanced cardiomyopathy.

Long-standing endocrine damage.

This is why early diagnosis matters.

38. Alcohol and Haemochromatosis

Excess alcohol intake can substantially worsen liver injury in a person with iron overload.

Therefore alcohol exposure can accelerate progression toward:

Fibrosis and cirrhosis.

Patients with hepatic iron overload should be assessed for coexisting liver risk factors.

39. Haemochromatosis – Note Form

Inheritance:

Autosomal recessive.

Gene:

HFE gene.

Chromosome 6.

Most important classic variant:

C282Y.

H63D is less strongly associated with severe disease.

Mechanism:

↓ effective hepcidin signalling.

↓

↑ ferroportin activity.

↓

↑ intestinal iron absorption.

↓

Progressive tissue iron deposition.

Men:

Usually earlier and more severe clinical expression.

Women:

Menstruation/pregnancy delay iron accumulation.

Often later presentation.

40. Clinical Features – Note Form

Cirrhosis.

Skin bronzing.

Diabetes mellitus.

Cardiomyopathy.

Chondrocalcinosis/CPPD arthropathy.

MCP joint disease.

Hypogonadism.

41. Diagnosis – Note Form

Transferrin saturation ↑

often an early biochemical clue.

Ferritin ↑

suggests increased iron stores but is nonspecific.

HFE gene testing

particularly C282Y.

MRI liver iron

useful non-invasive assessment.

Liver biopsy

selected cases rather than routine diagnosis for everyone.

42. Treatment – Note Form

First-line:

Therapeutic venesection.

↓

Removes haemoglobin-bound iron.

↓

Stored iron used to make new RBCs.

↓

Total body iron falls.

Chelation:

Deferoxamine/desferrioxamine or other chelators.

Used mainly when:

Venesection cannot be performed.

43. Important Corrections to the Original Notes

The statement:

“AR”

is correct for classical HFE-associated hereditary haemochromatosis.

The statement:

“More common and more severe in men”

is broadly correct clinically, largely because women lose iron physiologically through menstruation and pregnancy.

The diagnosis is better described as:

↑ TRANSFERRIN SATURATION + ↑ FERRITIN → consider HFE genetic testing.

Serum iron alone is:

Not sufficient for diagnosis.

The major genetic association is:

C282Y homozygosity.

H63D is a recognised HFE variant but usually has:

Much lower clinical penetrance.

Liver biopsy is no longer routinely necessary in every patient.

MRI and non-invasive fibrosis assessment have reduced the need for biopsy.

The treatment statement should be refined from:

“Venesection, desferrioxamine”

to:

VENESECTION IS THE STANDARD FIRST-LINE TREATMENT FOR MOST HEREDITARY HAEMOCHROMATOSIS.

IRON CHELATION IS RESERVED FOR SELECTED PATIENTS WHO CANNOT UNDERGO VENESECTION.

Key Clinical Pattern

For rapid recall:

HAEMOCHROMATOSIS → AR HFE DISORDER → ↓ HEPCIDIN EFFECT → ↑ INTESTINAL IRON ABSORPTION.

Think of:

LIVER → CIRRHOSIS.

SKIN → BRONZING.

PANCREAS → DIABETES.

HEART → CARDIOMYOPATHY.

JOINTS → MCP ARTHROPATHY + CHONDROCALCINOSIS.

ENDOCRINE → HYPOGONADISM.

For diagnosis:

↑ TRANSFERRIN SATURATION + ↑ FERRITIN → HFE TESTING.

For treatment:

HEREDITARY HAEMOCHROMATOSIS → VENESECTION.

SECONDARY TRANSFUSIONAL IRON OVERLOAD → OFTEN IRON CHELATION.